No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)?
Zhejiang Xianju Pharmaceutical (002332.SZ): obtained the domestic production pharmaceutical registration certificate for Deoxymethytestosterone tablets.
On March 10, according to Gelonghui, Zhejiang Xianju Pharmaceutical (002332.SZ) announced that the company recently received the "Pharmaceutical Registration Certificate" (Certificate No.: 2025S00652) approved by the National Medical Products Administration for Desogestrel and Ethinyl Estradiol Tablets, and the company's Desogestrel and Ethinyl Estradiol Tablets have been approved for registration. The specification of Desogestrel and Ethinyl Estradiol Tablets is 0.15 mg of Desogestrel and 20 mcg of Ethinyl Estradiol per tablet, with the reference formulation being the Desogestrel and Ethinyl Estradiol Tablets marketed in the EU under the brand name Mercilon. The reference formulation of Desogestrel and Ethinyl Estradiol Tablets was developed by N.V. Organon in the Netherlands.
Xianju Pharma's Unit Passes US FDA's Inspection of Workplace
Zhejiang Xianju Pharmaceutical's (002332.SZ) subsidiary Taizhou Xianju passed the USA FDA on-site inspection.
Zhejiang Xianju Pharmaceutical (002332.SZ) released an announcement that its wholly-owned subsidiary Taizhou Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as...)
Zhejiang Xianju Pharmaceutical (002332.SZ): Obtained the domestic production pharmaceutical registration certificate for Hekouyansuan Sodium Tablets.
Gelonghui, February 13th丨Zhejiang Xianju Pharmaceutical (002332.SZ) announced that it has recently received the "Drug Registration Certificate" for Beclometasone Sodium Tablets (Certificate Number: 2025S00441) approved by the National Medical Products Administration, and the company’s Beclometasone Sodium Tablets have been approved for registration. Beclometasone Sodium Tablets have a specification of 20μg (measured as Beclometasone Sodium), with the reference formulation being the original imported Beclometasone Sodium Tablets, marketed under the name Dena. The reference formulation for Beclometasone Sodium Tablets was developed by Toray Industries, Inc. and was approved in Japan in January 1992.
Little Excitement Around Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Earnings As Shares Take 27% Pounding
